UA-45667900-1

Tuesday 4 June 2019

Meningeal Lymphatics in Autism - at least two possibly relevant dysfunctions




  
I am always surprised how popular some posts with complicated titles are on this blog. Meningeal lymphatics in Bart Simpson speak would be “brain plumbing”.  Today we discover that:-

·        Immune cells can enter the brain by climbing up the brain’s plumbing pipes, entering originally via lymph nodes outside the brain

·        Those same plumbing pipes get blocked and waste is not free flowing out of the brain. The blockage may be at a brain-draining lymph node.

Today’s post follows up some research that I think Tyler highlighted a long time ago, about the recent discovery that the brain has its own lymphatic system.





                       
Human Lymphatic System before 2015              Human Lymphatic System after 2015




In a stunning discovery that overturns decades of textbook teaching, researchers at the University of Virginia School of Medicine have determined that the brain is directly connected to the immune system by vessels previously thought not to exist. That such vessels could have escaped detection when the lymphatic system has been so thoroughly mapped throughout the body is surprising on its own, but the true significance of the discovery lies in the effects it could have on the study and treatment of neurological diseases ranging from autism to Alzheimer's disease to multiple sclerosis.

Structural and functional features of central nervous system lymphatic vessels


Editorial Summary

A lymphatic system for the brain

The central nervous system is under constant immune surveillance, but the exit route for immune cells has been unclear as the brain was thought to lack a classical lymphatic drainage system. Jonathan Kipnis and colleagues now show that the brain does indeed possess functional lymphatic vessels, located in the meninges, and that these vessels are able to carry both fluid and immune cells from the cerebrospinal fluid. The presence of a classical lymphatic system in the central nervous system suggests that current thinking on brain tolerance and the immune privilege of the brain should be revisited. Malfunction of the meningeal lymphatic vessels could be a root cause of a variety of neuroimmunological disorders. 

  

Knowledge has moved on a bit further since 2015 and hence today’s post, but the research is focused on MS and Alzheimer’s rather than autism.

The lymphatic system carries a clear fluid call lymph.

The lymphatic system has multiple interrelated functions

·         It is responsible for the removal of interstitial fluid from tissues
·         It absorbs and transports fatty acids and fats as chyle from the digestive system
·         It transports white blood cells to and from the lymph nodes into the bones
·         The lymph transports antigen-presenting cells, such as dendritic cells, to the lymph nodes where an immune response is stimulated.

The discovery in 2015 - A lymphatic system for the brain

The central nervous system is under constant immune surveillance, but the exit route for immune cells has been unclear as the brain was thought to lack a classical lymphatic drainage system.

Jonathan Kipnis discovered that the brain does indeed possess functional lymphatic vessels, located in the meninges, and that these vessels are able to carry both fluid and immune cells from the cerebrospinal fluid. The presence of a classical lymphatic system in the central nervous system suggests that current thinking on brain tolerance and the immune privilege of the brain should be revisited. Malfunction of the meningeal lymphatic vessels could be a root cause of a variety of neuroimmunological disorders.






When a tissue is infected by a pathogen, like a virus, bacteria, or parasite, bits and pieces of the offending pathogen end up in the lymph. These pieces, along with immune cells from the infected tissue, reach the lymph node, and the cells in the lymph node then react to coordinate a specific immune response to the pathogen. Thus, the system not only allows for recirculation of bodily fluid, but it also provides a means for the immune system to sift through material from around the body in order to scan for infection. Without lymphatics, fluid would build up in body tissues, and there would be no way to alert the adaptive immune system to invading pathogens.


Alzheimer's, Autism, MS and Beyond

The unexpected presence of the lymphatic vessels raises a tremendous number of questions that now need answers, both about the workings of the brain and the diseases that plague it. For example, take Alzheimer's disease. "In Alzheimer's, there are accumulations of big protein chunks in the brain," Kipnis said. "We think they may be accumulating in the brain because they're not being efficiently removed by these vessels." He noted that the vessels look different with age, so the role they play in aging is another avenue to explore. And there's an enormous array of other neurological diseases, from autism to multiple sclerosis, that must be reconsidered in light of the presence of something science insisted did not exist

It is now suggested that several organs may be sites at which CNS-specific T cells become ‘licensed’ to acquire an appropriate migratory profile that will allow them to infiltrate the CNS.

What that means is an immune dysfunction far away from the brain and its blood brain barrier defences can send its messengers up the brain’s drain pipes and directly into the brain.

By closing the drain pipes you can prevent serious brain inflammation like that found in Multiple Sclerosis.

 Kipnis’ idea is to target major neurological disorders through therapeutic manipulation of peripheral structures, such as lymphatic vessels.  In other words, you block the inflammatory signals from entering the brain.

The research has now shown that this is indeed achievable in the mouse model of multiple sclerosis.

The problem with blocking the flow through the pipes is that you need them to be free flowing to avoid dementia and cognitive decline.  The Alzheimer’s research suggests that opening up the pipes wide to clear away accumulated junk in the brain might well stave off the disease.

The solution might involve some complex plumbing adjustment.

For old people it might be key to modify the lymphatic system inside the brain, so as to open those blocked pipes.  It may be that in some autism a variant of this problem also exists.  There is a section on this later in the post, with some case histories.
For people with MS and inflammatory-type autism it might be the case of closing the pipes at a clever location in the lymphatic system outside the brain to stop inflammatory messengers entering the lymph system and heading up into the brain. 

While autism research is rarely class-leading, MS research and Alzheimer’s research attracts plenty of smart scientists and research dollars.  This means that you may want to keep an eye on research in those two diseases.

Now we look at the research:

  • Multiple Sclerosis
  • Alzheimer’s
  • Autism


Multiple Sclerosis

Great strides are being made in MS research and some of the off-label therapies like Ibudilast, referred to in this autism blog, are showing promise in clinical trials.

Brain-draining lymph nodes exist outside the brain and you can actually measure how much CSF is flowing out of the brain.  In older brains the flow rate is much less, as if the drains have got clogged up. 

Brain-draining lymph nodes also allow inflammatory messengers to enter the central nervous system (CNS) that was supposed to be kept safe behind the blood brain barrier.

Brain's lymphatic vessels as new avenue to treat multiple sclerosis

Vessels carry mysterious message from brain that causes MS, research suggests

                          
Lymphatic vessels that clean the brain of harmful material play a crucial role in the development and progression of multiple sclerosis, new research from the University of Virginia School of Medicine suggests. The vessels appear to carry previously unknown messages from the brain to the immune system that ultimately trigger the disease symptoms. Blocking those messages may offer doctors a new way to treat a potentially devastating condition that affects more than 2 million people.
The discovery comes from the lab of UVA researchers who identified the lymphatic vessels surrounding the brain, vessels that textbooks long insisted did not exist. In an exciting follow-up, the researchers have determined that the vessels play an important role in not only multiple sclerosis but, most likely, many other neuroinflammatory diseases and in dangerous brain infections.
"Our data suggests that there is a signal coming from the brain to the lymph nodes that tells immune cells to get back into the brain, causing the [multiple sclerosis] pathology," said researcher Antoine Louveau, PhD, of UVA's Department of Neuroscience and its Center for Brain Immunology and Glia (BIG). "This is an important proof of principle that exploring the role of these vessels in different neurological disorders, including multiple sclerosis, is worth it."
Stopping Multiple Sclerosis
The researchers at UVA, led by Jonathan Kipnis, PhD, were able to impede the development of multiple sclerosis in mice by targeting the lymphatic vessels surrounding the brain. They used multiple strategies to block the lymphatics or destroy them with a precision laser. All led to the same outcome: a decrease in the number of destructive immune cells capable of causing paralysis.
"The idea was to prevent more widespread damage to the nervous system," said researcher Jasmin Herz. "If communication of brain inflammation through lymphatic vessels is the root cause of multiple sclerosis, therapies targeting these vessels could be clinically important."
The message from the brain that appears to drive multiple sclerosis remains poorly understood. The researchers can tell the message is being sent, and they can tell what it is instructing the immune system to do, but they don't yet know what mechanism the brain is using to send it. "I think the next step in this specific research is to identify what that signal is. Is it a cellular signal, is it a molecular signal?" Louveau said. "And then to try to target that signal specifically."
The researchers noted that removing the vessels did not stop multiple sclerosis entirely. That suggests there are likely other factors at play -- and much more for scientists to explore.

An Important Proof of Principle
UVA's new research offers important insight into the function and role of the lymphatic vessels that connect the brain to the immune system. In most aspects, they work exactly as scientists would expect -- just like other lymphatic vessels in the body.
"Meningeal lymphatic vessels are quite small compared to other lymphatics in the body, and we and others wondered if this might limit the amount and size of cargo they can pass through," Herz said. "During inflammation, they did not change in size or complexity much, but what was really exciting to discover [was that] they allowed whole immune cells to traffic through them, and we found the molecular cues for that."
the lab's recent research also highlights the complexity doctors face when trying to But manipulate the vessels to benefit human health. For example, blocking the vessels had a benefit in the multiple sclerosis model, but the lab has also shown that the vessels' healthy function is vital to staving off Alzheimer's disease and preventing the cognitive decline that comes with age.
That means that it's unlikely that stopping MS could be as simple as blocking the flow inside the vessels. It also suggests that there is probably no one treatment approach that will work for every neurological disorder. But the emerging importance of the vessels offers doctors an exciting new avenue for tackling neurological diseases.
"These findings on the role of brain-draining lymphatic vessels in MS, together with our recent work on their role in Alzheimer's disease, demonstrate that the brain and the immune system are closely interacting. When these interactions go out of control, pathologies emerge," said Kipnis, chairman of UVA's Department of Neuroscience and director of the BIG Center. "The idea that we could target major neurological disorders through therapeutic manipulation of peripheral structures, such as lymphatic vessels, is beyond exciting. Through our collaboration with PureTech Health, we hope to bring these laboratory findings to improve patients' lives one day."
Kipnis recently signed a deal with biopharmaceutical company PureTech Health to explore the potential clinical applications of his discoveries.


CNS lymphatic drainage and neuroinflammation are regulated by meningeal lymphatic vasculature


Neuroinflammatory diseases, such as multiple sclerosis, are characterized by invasion of the brain by autoreactive T cells. The mechanism for how T cells acquire their encephalitogenic phenotype and trigger disease remains, however, unclear. The existence of lymphatic vessels in the meninges indicates a relevant link between the CNS and peripheral immune system, perhaps affecting autoimmunity. Here we demonstrate that meningeal lymphatics fulfil two critical criteria: they assist in the drainage of cerebrospinal fluid components and enable immune cells to enter draining lymph nodes in a CCR7-dependent manner. Unlike other tissues, meningeal lymphatic endothelial cells do not undergo expansion during inflammation, and they express a unique transcriptional signature. Notably, the ablation of meningeal lymphatics diminishes pathology and reduces the inflammatory response of brain-reactive T cells during an animal model of multiple sclerosis. Our findings demonstrate that meningeal lymphatics govern inflammatory processes and immune surveillance of the CNS and pose a valuable target for therapeutic intervention.

Discussion

Here we show that meningeal lymphatic vessels sample macromolecules and immune cells from the CSF and serve as an important conduit for CNS drainage. We also describe structural features of spinal cord meningeal lymphatics. We expand on our understanding of immune-cell trafficking via the meningeal lymphatic vessels to the draining lymph nodes, which is primarily dependent on CCR7. Using a pharmacological method that we adopted to specifically ablate meningeal (or nasal) lymphatic vessels, we demonstrated that the nasal route drains directly into the sCLNs, while the meningeal lymphatic route drains into both the dCLNs and sCLNs. RNAseq analysis of LECs from mouse meninges, diaphragm, and skin revealed that the meningeal lymphatic vessels exhibited a unique transcriptional profile, which, under local inflammatory conditions, might underlie the distinct behavior of meningeal lymphatics. Attenuation of EAE was obtained after surgical and pharmacological blockade of lymphatic function, suggesting that drainage contributed to the activation of encephalitogenic T cells in the lymph nodes. Supporting this notion, reduction of meningeal lymphatic drainage reduced interactions of 2D2 T cells with local antigen-presenting cells. RNA-seq of activated 2D2 T cells isolated from dCLNs showed that T cells from mice lacking lymphatic drainage acquired a different phenotype from that of controls. These findings warrant further research to identify the cellular (and/or molecular) mediators draining from the CNS and driving T cell encephalitogenicity. Meningeal lymphatic vessels are embedded within the dura. This raises an obvious question: how can macromolecules and immune cells drain from the CSF into meningeal lymphatic vessels, given that the arachnoid mater is supposedly impermeable to CSF45? We noticed, however, that certain spots along the meningeal lymphatics could be seen to take up the tracer from the CSF almost immediately after its injection, whereas tracer uptake along remaining parts of the vessels was slower. Subsequent experiments revealed certain spots along the meningeal lymphatics where the vessel structure was more complex and ramified and where extensions were exposed to the CSF. The structure of these lymphatic sprouts is reminiscent of peripheral-tissue lymphatic buttons, which serve as entry gates into the lymphatic vasculature. Further experiments using electron microscopy technique will be necessary to demonstrate that the meningeal lymphatic vessels are physically crossing the arachnoid mater. Previous reports have implicated the cribriform plate as a major player in the passage of immune cells from the CNS to its draining lymph nodes. Furthermore, a recent study has challenged the potential contribution of the meningeal lymphatics in the drainage of CSF into the CLNs6 . Here using live-imaging, our data (supported by others46) clearly demonstrates the uptake by meningeal lymphatics of tracers injected into the CSF. Our observations, however, do not exclude alternative routes as previously suggested. In the present study, we injected exogenous cells into the cisterna magna and also observed cells in the nasal mucosa and associated lymphatics. However, we could not detect any T cells on the nasal side of the cribriform plate under physiological conditions. Moreover, we labeled endogenous meningeal T cells using laser photoconversion but could not detect any labeled cells in the nasal mucosa. It is possible that if photoconversion of meningeal T cells was complete, some crossing of the cribriform plate by meningeal T cells could have been observed. Furthermore, the speed of injection (and, hence, change in intracranial pressure) appears to be a major factor in facilitating crossing of the cribriform plate by CNS immune cells. Our results thus suggest that the cribriform plate in all probability does not represent a major physiological immunerelevant exit route. This structure has been shown, however, to play an important role in the regulation of CSF homeostasis, since its surgical blockade results in an immediate and constant increase in CSF pressure47. Our results also show that chronic neuroinflammation is accompanied by expansion of the lymphatic vasculature localized around the cribriform plate (as opposed to brain and spinal cord meningeal lymphatics), suggesting that the nasal region might have a more important function at later stages of disease development. Several organs (such as lungs48, for example) have been suggested as sites at which CNS-specific T cells become ‘licensed’ to acquire an appropriate migratory profile that will allow them to infiltrate the CNS. Our data suggest that dCLNs could be another site for T cell licensing or reactivation. Dendritic cells migrating from different tissues have been shown to uniquely influence T cell activation and migration49, and MOG-loaded dendritic cells reportedly activate T cells in the CLNs before their migration into the CNS50. In the context of EAE (both induced and spontaneous), excision of the brain-draining lymph nodes has been shown to delay or attenuate disease development38–40. In spontaneous models, limitation of the drainage of MOG into the dCLNs, thereby preventing activation of MOG-specific T cells, is a likely mechanism. A similar scenario might apply when meningeal lymphatics are ablated. It is important to note that meningeal lymphatic ablation only attenuates and ameliorates EAE but does not completely stop it, suggesting that other routes are involved. Although no side effects were found when using the Visudyne approach, future development of targeted techniques will allow researchers to discern the role of anatomically distinct lymphatics in EAE. Overall, the work described here provides the first characterization, to our knowledge, of the meningeal lymphatic system in the context of brain immunity and neuroinflammation and opens the way to a better understanding of brain immune surveillance and the generation of CNS-directed immune responses. These results might help to uncover the etiology of the immune imbalance typical of neuroinflammatory disorders, with promising implications for therapy

  
                           

Dementia including Alzheimer’s

Brain discovery could block aging's terrible toll on the mind

Faulty brain plumbing to blame in Alzheimer's, age-related memory loss -- and can be fixed


Aging vessels connecting the brain and the immune system play critical roles in both Alzheimer's disease and the decline in cognitive ability that comes with time, new research reveals. By improving the function of the lymphatic vessels, scientists have dramatically enhanced aged mice's ability to learn and improved their memories. The work may provide doctors an entirely new path to treat or prevent Alzheimer's disease, age-related memory loss and other diseases. 
Kipnis and his colleagues were able to use a compound to improve the flow of waste from the brain to the lymph nodes in the neck of aged mice. The vessels became larger and drained better, and that had a direct effect on the mice's ability to learn and remember. "Here is the first time that we can actually enhance cognitive ability in an old mouse by targeting this lymphatic vasculature around the brain," Kipnis said. "By itself, it's super, super exciting, but then we said, 'Wait a second, if that's the case, what's happening in Alzheimer's?'"
The researchers determined that obstructing the vessels in mice worsens the accumulation of harmful amyloid plaques in the brain that are associated with Alzheimer's. This may help explain the buildup of such plaques in people, the cause of which is not well understood. "In human Alzheimer's disease, 98 percent of cases are not familial, so it's really a matter of what is affected by aging that gives rise to this disease," said researcher Sandro Da Mesquita, PhD. "As we did in mice, it will be interesting to try and figure out what specific changes are happening in the old [brain] lymphatics in humans so we can develop specific approaches to treat age-related sickness."
Kipnis noted that impairing the vessels in mice had a fascinating consequence: "What was really interesting is that with the worsening pathology, it actually looks very similar to what we see in human samples in terms of all this aggregation of amyloid protein in the brain and meninges," he said. "By impairing lymphatic function, we made the mouse model more similar to human pathology."

Treating -- or Preventing -- Alzheimer's
The researchers now will work to develop a drug to improve the performance of the lymphatic vessels in people. (Kipnis just inked a deal with biopharmaceutical company PureTech Health to explore the potential clinical applications of his discoveries.) Da Mesquita also noted that it would be important to develop a method to determine how well the meningeal lymphatic vasculature is working in people.
The researchers believe that the best way to treat Alzheimer's might be to combine vasculature repair with other approaches. Improving the flow through the meningeal lymphatic vessels might even overcome some of the obstacles that have doomed previously promising treatments, moving them from the trash heap to the clinic, they said.
It may be, though, that the new discovery offers a way to stave off the onset of Alzheimer's to the point that treatments are unnecessary -- to delay it beyond the length of the current human lifespan.
"It may be very difficult to reverse Alzheimer's, but maybe we would be able to maintain a very high functionality of this lymphatic vasculature to delay its onset to a very old age," Kipnis said. "I honestly believe, down the road, we can see real results."


Outflow of cerebrospinal fluid is predominantly through lymphatic vessels and is reduced in aged mice


Cerebrospinal fluid (CSF) has been commonly accepted to drain through arachnoid projections from the subarachnoid space to the dural venous sinuses. However, a lymphatic component to CSF outflow has long been known. Here, we utilize lymphatic-reporter mice and high-resolution stereomicroscopy to characterize the anatomical routes and dynamics of outflow of CSF. After infusion into a lateral ventricle, tracers spread into the paravascular spaces of the pia mater and cortex of the brain. Tracers also rapidly reach lymph nodes using perineural routes through foramina in the skull. Using noninvasive imaging techniques that can quantify the transport of tracers to the blood and lymph nodes, we find that lymphatic vessels are the major outflow pathway for both large and small molecular tracers in mice. A significant decline in CSF lymphatic outflow is found in aged compared to young mice, suggesting that the lymphatic system may represent a target for age-associated neurological conditions 


Functional aspects of meningeal lymphatics in ageing and Alzheimer’s disease




Autism

While Kipnis is busy developing a drug to improve the lymphatic drainage from the aging brain, some people believe they can achieve something similar via massage.

I have no idea if this really is possible, but this is the idea being practised on children with autism in Italy.

So, because this is after all an autism blog, let’s see what the Italian have been up to.





In this study we report the results of a protocol for improving brain lymphatic flow in autism through lymphatic drainage massage, a technique successfully used in a variety of conditions where intracranial lymphatic circulation is hampered by obstacles at the level of deep cervical nodes. At the end of May 2018, the Biomedical Centre for Autism Research and Treatment started implementing a protocol of manual lymphatic drainage of the deep cervical nodes on autistic subjects. By October 2018, several scores of patients had been treated with this protocol. In this report, we describe the cases of three autistic patients for whom manual lymphatic massage was remarkably effective. To our knowledge, this is the first report of lymphatic drainage massage at the level of the deep cervical nodes in autism. Symptomatic improvement was robust and we attribute these results to the effects of the massage on the intracranial lymph or sometimes referred to as the glymphatic circulation with improvement of brain lymphatic drainage believed leading to a decrease of neuroinflammation. In addition to stimulating lymphatic drainage, we postulate that the protocol may serve also as vagus nerve stimulation. The protocol also targets the larynx in a manner similar as described for laryngeal manual therapy for the treatment of dysphonia, and this factor may be contributing to the overall improvement of symptoms, with particular reference to speech. Based on the cases described in this report and on our ongoing research, we are convinced that this type of inexpensive, harmless and easy-to-implement approach of manual lymphatic drainage can be beneficial to autistic patients and represents a new and promising treatment. We expect that the described protocol will play a central role in future treatments for autism, both alone and in combination with other therapies such as behavioral therapies or nutritional interventions.

Case Reports

Patient 1:

Male, 2 years and 9 months old at the time of implementing the manual lymphatic drainage protocol. The patients showed first signs of autism at 20 months of age when he lost the few words he had learned, lost eye contact, stopped responding when called, and began bizarre behaviors - motor stereotypies - that included flapping. Subsequently, this patient developed crises of anger and violent tantrums, in particular when contradicted. The patient did not show significant bio-humoral alterations with the exception of slightly elevated platelet count and IgE. The patient had frequent bowel movements with very soft and hypocholic feces. Three days after implementation of the manual lymphatic drainage protocol, the patient spontaneously begun speaking a few words and eating without the need of assistance, properly using the tableware. Bowel movement were reduced to two movements per day with well-formed feces. The patient begun showing curiosity toward new foods and flapping progressively disappeared. In the following two months, he significantly increased the complexity of his vocabulary and the ability to appropriately follow complex instructions. Stereotypies disappeared and ability of learning during behavioral therapies significantly improved.

Patient 2:

Female, 9 years old at the time of implementing the manual lymphatic drainage protocol, with confirmed diagnosis of early-onset autism and recurrent allergic asthma requiring desloratadine treatment. The most prominent autism symptoms were motor stereotypies, speech limited to very simple sentences, and significant delay in learning. Immediately after implementation of the manual lymphatic drainage, a slight, temporary, enlargement of latero-cervical nodes lasting for a few days was noted, possibly due to mobilization of lymph. Evident improvement of autistic symptoms consisted in spontaneous, faster and easier learning at school with increased alertness and focus. Ability in performing coordinated fine movements significantly increased and the patient began to write; this in turn resulted in increased self-esteem. Motor stereotypies significantly decreased and personal autonomy significantly increased.

Patient 3:

Male, 6 years and 6 months old at the time of implementing the manual lymphatic drainage protocol. The patients showed first signs of autism at 15 months of age when he stopped developing speech, lost eye contact, stopped responding when called and refrained from social interactions. A diagnosis of atypical autism with hyperactivity and attention deficit was proposed at the age of 5. The child had chronic allergic rhinitis and sinusitis with persistent nasal congestion that caused open mouth breathing. The patient was very selective in his eating habits and only ate a few types of fried foods. Following implementation of the manual lymphatic drainage protocol, chronic nasal congestion was rapidly resolved, and nose breathing was reestablished. Eating habits were significantly improved and the patient began eating a variety of healthier foods. The patient also showed improvement in socialization; began to look at other children, trying to imitate their actions. Also, significant improvements in speech were observed with the patient speaking more complex sentences with better pronunciation.



Conclusion

I think it is very likely that something in today’s post is indeed very relevant to much autism.

Now we know not to blame only the vagus nerve for transmitting inflammatory signals from the body to the brain.

Hopefully the researchers will eventually pursue their original idea from 2015 that the study of meningeal lymphatics might lead to autism therapies.

We are of course at liberty to learn from the Alzheimer’s and MS research and develop our own therapies.






Wednesday 29 May 2019

McMaster University Autism iPS Research Study


Dr Karun Singh   


This is a Guest Post by our reader AJ


McMaster University Autism iPS Research Study

First, a very big thank you to Peter for kindly offering to allow me to write this guest post.

It is with great excitement that I am announcing the launch of what I believe is one of the most promising research projects in autism today – McMaster University’s Autism iPS Research Study.  In fact, I have been given the great privilege of helping McMaster University raise funds and awareness for this incredible endeavor. For those of you that aren’t familiar with McMaster University, it is Canada’s most research-intensive University, located in Hamilton, Ontario (just west of Toronto).

What is the McMaster University Autism iPS Research Study?

This research is being led by Dr. Karun Singh at McMaster University. You can learn more about Dr. Singh and his research at

 https://sccri.mcmaster.ca/people/karun-singh.  

The intent of this research is to study reprogrammed neurons from individuals with autism and gain key insights into the affected pathways that result in the various issues seen with ASD. Dr. Singh’s approach requires that the ASD child, and each parent, provide a blood sample and these blood samples are reprogrammed (for those of you familiar with iPS cells) into neurons. Dr. Singh studies the ASD child’s neurons, using the parental iPS neurons as controls.

To supplement the research, Dr. Singh also uses a tool called BioID. This tool uses biotinylation, or the process of attaching biotin to proteins and other macromolecules, to determine what the mutant version of an affected protein (assuming a causative mutation is known) is doing differently than the normal version of the same protein. 

Once Dr. Singh has conducted his research into an ASD individual’s neurons and completed his BioID analyses, the next step in the project is to run a variety of selected compounds to screen for compounds that will address the underlying cellular mechanisms that are causing the condition.  

In summary, Dr. Singh’s research at McMaster intends to:

i) Use BioID to elucidate what a mutant protein is doing differently than the normal protein (where a genetic mutation is known)
ii) Use iPS neurons via reprogramming to study ASD neurons (and the parental controls) to determine what is causing symptoms in that particular individual
iii) Once the above two are completed, select compounds for testing against the iPS neurons to see if any are able to address the underlying issue causing the condition

What Dr. Singh and McMaster need for this project to succeed

When I first spoke with Dr. Singh and understood what he intended to do, I was naturally very excited. This research can clearly make an enormous impact in moving the science ahead and helping our children get the treatment they need. But then I learned about the one thing that was preventing him from moving forward – funding. As some you may know, researchers often have challenges in obtaining funding for their research, even when working at great institutions and pursuing very worthwhile research.

Like many of you, as a proactive parent it struck me that this endeavor is so clearly worthwhile that I offered to both pursue funding for it and also raise awareness. Rather than waiting for government funding, I believed that affected families, individuals and organizations who understand the importance of this work would help fund it and allow it to move forward.

So, to each parent reading this, I’m asking for you to consider supporting this research in the following ways:

1. DONATE: McMaster University has a funding page for this specific endeavor at impacths.mcmaster.ca/autismips – kindly give as generously as you can as each dollar is spent specifically on this research. The great news is that McMaster is able to provide tax receipts for Canadian donors. If you are living outside Canada and are considering making a donation to McMaster University’s Autism iPS Research Fund, there may be more information you need. There are different giving options for international donors in the following countries: USA, United Kingdom, Hong Kong. If you reside in one of those countries, please do not give online, instead contact the fundraising team at impacths@mcmaster.ca to receive additional information.

If you’re outside of Canada, USA, United Kingdom, and Hong Kong, please donate online or by contacting impacths@mcmaster.ca

This project requires significant funding to move ahead, as the reprogramming of neurons alone can cost up to $12,000 CAD per individual. As the research requires that the child and both parents have their blood reprogrammed into neurons, we estimate that the total research costs could be roughly $50,000 CAD per genetic mutation studied in the lab.

If you are interested in supporting the research tied to a specific genetic mutation with research costs of $50,000 CAD, please contact Simone Moran directly (moransim@mcmaster.ca). Simone will make certain that your area of interest aligns with the academic priorities and help liaise with the research team if appropriate. 

2. ADVOCATE: Become an advocate for this project. This is a very important ask. Kindly let everyone you know, especially those affected by ASD, about this research at McMaster University so that either they can donate, advocate, or participate in this research. Further, if you would like to pursue getting charitable donations from the company you work for, organizations you are familiar with (such as an ASD group focused on a particular gene, etc.), or individuals with the financial flexibility to make such donations, please do so. You can also share updates about Dr. Singh’s work such as this article: https://brighterworld.mcmaster.ca/articles/mcmaster-helps-provide-new-insight-on-gene-mutations-associated-with-autism/
   
3. PARTICIPATE: In addition to the need for funding, Dr. Singh’s lab is in need of more participants for this research. The McMaster team is interested in obtaining the necessary blood samples from a significant number of individuals affected by ASD. If your family would consider being part of the research, please contact Dr. Singh’s team by contacting Dr. Elyse Rosa at rosae@mcmaster.ca to determine if you qualify. It is important to remember that the details of each child’s specific case will need to be assessed by the research team to determine if they are consistent with the aims of this research.

*Please note that there is no link between donations and participation in this research. Both matters are handled by separate teams, in a confidential manner.

This research project is just starting, and funding is essential to continue to move it forward. That is why it is so important that we raise as much money as possible to allow Dr. Singh to apply BioID and iPS reprogramming to as many ASD children as possible. Again, please donate as much as you can, encourage others to give, and get the message out about this incredible opportunity.

From personal experience, I can tell the community that as impressive as Dr. Singh’s qualifications are, and as impressive as the resources at McMaster University are, that what has impressed me the most is Dr. Singh’s dedication to helping families with ASD. He truly wants to better understand the causes of this condition at a cellular level. As Dr. Singh’s team makes discoveries in this endeavor, they will be sharing their findings with researchers around the world for the benefit of all.

If we (with the help of each and every single one of you) can get Dr. Singh’s ambitious research fully funded, then the positive impact on ASD families will be enormous. I really believe in Dr. Singh and I know that with adequate funding, he will get us much closer to finding better treatments for our kids.

I hope everyone is as excited as I am about this endeavor and that each person who reads this post will do everything you can do help raise awareness and funds to make this project a big success. This is the right project, at the right time, with the right research team – please join me in doing everything you can to help Dr. Singh succeed!






Thursday 23 May 2019

Take Away Points from Thinking Autism 2019 Conference in London


This is not a summary of the recent conference I attended in London, it is just the impressions I left with, which will be very different to those of the delegates and the other speakers.

Hopefully I do not upset too many people.

Here is information on the conference and PDF versions of the two presentations I gave.






https://drive.google.com/file/d/1ZaK0C6wiTz8SrqFVwNbe6B8bGpSbYpNv/view?usp=sharing ht






This is the only autism event I have ever attended, other than a discussion over lunch at a university reunion where someone organised a meeting for those from our year with an interest in autism. Other than that, I have really only ever met a handful of autism parents face to face.

I did meet our reader Petra in Thessaloniki a few years ago.  As expected, Petra is a very nice person in reality and not just in the comments on this blog

This weekend I met face to face with Agnieszka, Natasa who comments frequently and helps run the Think Autism charity in the UK, as well as many others who comment less frequently. I met my first MAPS-type doctor, Richard Frye and had a chat over lunch. It was a bit one-sided because I know a lot about him and his research and he knows nothing about me and my online collection of research.

I did meet some of the UK doctors who have a child with autism and an interest in doing something about it.  I genuinely wish them all the best in reforming the system.

Yes, I do actually exist

One teacher from North London said that she had been wondering if I really exist. Now she knows I do.

Why does everyone seem to know you?

There is a magazine for autism parents in the UK and the lady who runs it came up to me to give me her card and asked why she had never heard of me, but so many others had.  The world has changed and blogs have advantages over print media - people like the comments and the hyperlinks.

Yes, an Alternative Reality for Autism

I was told a few years ago that I appear to live in a different world to most other people, at least when it comes to autism.  I suppose that is true and I do only very rarely encounter that other world.  This conference was one of those rare events.

In my world anything is possible, until proven otherwise. I prefer to keep it that way.

Many people do have a choice and over the decades you will get to see the consequences of those choices; for better or worse.

Since not all parents are science wizards, there should be some support from both public health and educational services to ensure every child has a basic level of provision.  That basic level is not very high anywhere in the world.

If you want more you have to go and find it.

How much effort do you really want to make? What short term discomfort are you willing to take to ensure a brighter future?

I am surprised how much variation there is.  Some parents will do just about anything, while some others do nothing.

Personally, I am a proactive person. When something is broken, I try to fix it. If the “expert” gives me lame excuses, I do not accept them; I look for different solutions and maybe a different “expert”. 

Clearly, I am far from typical.  Thank god.

I do not lie in bed at night wondering what will happen to my son when I am dead.  I do not get depressed about the curtailed life expectancy in severe autism; rather I think it is up to me to make a difference while I am still very much alive.  The future is very much determined by past actions.

Other people are very welcome to visit this alternative reality where an open-minded science-based approach is encouraged.  An open mind is actually more important than a clever mind.

I did mention to Dr Frye about Potassium Bromide (KBr) for autism/epilepsy and his first reaction was “child protective services!”, someone else once mentioned “that is for pets!”.  Actually, Potassium Bromide (KBr) was the original human drug for epilepsy and to this day is successfully used in Germany for treatment resistant pediatric epilepsy. It saves lives.  Untreated epilepsy will kill you. About 30% of epilepsy does not respond well enough to mainstream therapies. Numerous modern studies regarding KBr have been published.  You just have to keep an open mind.  The Germans, Japanese, Chinese may know something Americans do not.

I did get indirect feedback that an autism parent showed the German/Austrian KBr research to a leading US neurologist, I think it was Dr Chez, and his comment was that he wished he could prescribe it to patients. For the moment in the US it is dogs with epilepsy rather than children with Dravet’s Syndrome and others that benefit.

Italy has some nice doctors

I have noted before on my blog that within Europe, Italy seems very different. We had a presentation from a Gastroenterologist from Turin who has been studying the bowels of kids with autism for 15 years and regarded it as a perfectly normal thing to do. No UK Gastroenterologist would do this. We had a chat about Milan, which I am now becoming more familiar with due to my elder son studying there. The top Italian researcher Dr Fasano, whose research I have covered in this blog, has moved to the US.  (one less clever doctor in Italy).

Israel has some nice doctors

We took Monty to Israel earlier this year, but it was to see the historical sites rather than to see the doctors.  There were a couple of speakers from Israel talking about cannabis in autism. They were really interesting and “well-adjusted”, they know their area of research is a bit controversial, but they find a way forward. I did cover in a recent post that you can use PEA instead of cannabis and they are aware of this, but cannabis is their research drug. They say that PEA has fewer side effects.

In their medical practise they actively treat autism, which no medical doctor does in the UK.  

Poland has some nice doctors

We already knew that Agnieszka is busy helping people in Gdansk and much further afield.  She is busy helping the UK charity Thinking Autism.   A husband and wife research team came from Lublin to talk about the ketogenic diet with a very thorough science-based presentation. They suggest a PET scan might identify responders. I think this is actually just one very specific sub-type, because it relates “simply” to altered glucose uptake to the brain being the underlying biological problem.

America has the most Autism Doctors, by far, at least one of whom is also a nice guy

There are so many horror stories of American DAN-type doctors charging huge fees for consultations and testing, you might imagine them all to be evil. I have never consulted a DAN/MAPS doctor, but Dr Frye definitely is a good guy and very willing to share his knowledge with others.

I did actually put him on my Dean’s list a while back, with some encouragement from our reader Roger.

The United Kingdom has no “Autism Doctors”

Many of the parents I met were English and very many of them had all been seeing the same doctor, who was then banned from seeing patients with autism. In the United Kingdom autism is untreatable.

If you want treatment, call it something else like auto-immune encephalopathy.

I am so glad I do not live in the UK

Many parents in the UK really struggle to achieve anything meaningful in regard to treating autism. I am glad to live in a different reality where the main limiting factor is the science itself, not the absurd things the UK parents have to deal with.

Bumetanide Clinical Trial Success

We had the absurd situation recently when it seemed that in the second largest country in the EU, almost no hospitals wanted to participate in the Bumetanide Phase 3 European trial for autism.

Fortunately, one of the parents at the conference is a Psychiatrist working in London. He has an interest in autism, because his child has it and he is already involved in the Balvotam trial for autism. Hopefully his hospital will become another centre for the trial starting this summer, that would be a big success.

Come on Agnieszka, see more Patients

Lots of people ask me for my email address and you may have noticed I always encourage them to contact me in public on this blog. I do this for several reasons including.

I am not a doctor and I am not giving medical advice. The comments are just a public discussion tagged on to a blog written by a parent whose albeit lengthy scientific education was not in biology.

Some comments and the ensuing discussion are really interesting for other people and it would be a shame for it to be hidden away.

I do think people in Europe should be able to access safe, evidence-based, off-label therapies, of the kind that Dr Frye is openly prescribing at the Phoenix Children’s Hospital. This is not really permitted in the United Kingdom, although there is a tiny bit of “wriggle room” if you have money, perseverance and some knowledge yourself.

I did ask Agnieszka if she is going to get into the same kind of trouble in Poland that any doctor would in the UK, if she openly held an autism clinic. Apparently not. Is her husband going to like it? I suppose we will find out.

How many people would actually come to Poland for a one-stop diagnostic work-up, where you could choose from a menu of MRI, whole exome screening, sleep EEG, 24 hour EEG, full blood work up testing all the things Dr Frye would test in Phoenix, once you could actually get an appointment to see him. As our reader Roger has told us, it is not so easy to get an appointment to see Dr Frye.  I suggested having Dr Frye also review the data and that if it was clear that there were GI problems there could be a referral to our new friend in Turin who has been treating the guts of kids with ASD for 15 years. You could then proceed to actually trial the off-label drugs that were indicated. 

None of this is cheap, but it is much cheaper than doing the diagnostics in the US, or the UK if you could actually access it.

Then I was thinking why leave it at evidence-based therapies for autism. Why not treat other poorly managed neurological diseases like Multiple Sclerosis (MS), there are so many things that can be done and actually much cheaper than in the US.

Then I came down to earth and realized that actually very few parents, at least ones from the UK, would take out their wallet and pay for all these tests, even though it would be a fraction of the cost that they would pay in US.

In the United Kingdom people expect their healthcare to be free from cradle to the grave. If it is free, although you do pay via your taxes, you are not the customer. The patient is the consumer, but he/she has little say in the therapy. If you need eye glasses, you might spend a day trying on frames in different shops to see what suits you, but if you need an operation you will have little say in the type of operation, you will get what the guidelines says is the cost effective therapy. If you have prostate cancer, you will not get proton beam therapy, that was developed years ago to minimize the side effects by focusing the radiation onto only the affected tissue rather than zapping all the surrounding tissue and giving you possible severe side effects.    

Who would invest a few thousand pounds/dollars to diagnose their child’s autism as accurately as possible? And then start treatment.

It would be nice to think there would be a long line. I think there would initially be a line for prescriptions for bumetanide. The real idea though is to make a thorough investigation to rule out treatable ID, single gene autisms, metabolic dysfunctions etc, not to be a prescription signing service.

So, as I said to Agnieszka, don’t plan to give up your day job any time soon.  Have treating autism as a side-line, make a list of therapies that you think are evidence based. It would not include things like the Nemechek protocol, I think it would include things like Bumetanide, Dr Frye’s Leucovorin, Propranolol and the many existing drugs already tested in clinical trials.  For Nemechek you can buy his book, no doctor is needed.

Where are all the younger parents?

Given that I have one son already moved out of the country to go to University, I was expecting to be feeling old surrounded by all those young parents working out what to do with their very young children recently diagnosed with autism.  There were some parents in their 30s, but most were much older.

It was nice that at least one Grandpa was there, looking for ideas for his adult Grandson. I did actually make a point of pointing him towards the science relating to his issues.

The Microbiome comes from the Mother

This may be obvious, should not be forgotten and sounds quite catchy.

It does not matter so much what is in Dad’s microbiome. It does matter what is in his epigenome and of course his regular genes matter.

Mum/Mom provides here half of the child’s regular DNA, her epigenome, all of the mitochondrial DNA and all of the microbiome that filters through to the child during pregnancy and during delivery (assuming there was no C-section).


Conclusion  

Having spent a couple of days mainly with British parents dealing with autism, I came home and told everyone how glad I am that I do not live there.  It would drive me crazy!

They can wait for years to get a diagnosis

No doctor is supposed to treat autism, even comorbidities may go untreated, because that might imply you are treating autism.   But many people still think they have a world class healthcare system (in some areas this really is true).

US style free early intervention for very young children does not exist. 

They have a very backward-looking Autism Charity (NAS) that is dominant and supposedly represents them.

Provision of special schools is highly variable and often parents take legal action to get better provision.  This means the less able parents that do not know how to play the system have even less resources allocated to their kids. 

They have about 2,000 young people with autism locked up for years in small, poorly supervised, private mental institutions. Just today another horror story has been released about the abuse that can occur.



The end result is some pretty browbeaten parents.

I was once asked if I would speak in the US and I asked what they would like me to speak about, it was very much TREAT AUTISM NOW !!!  Those are my kind of people.  More dynamic, pushier and demanding more – it is the only way to be.

The Israeli clinicians at the conference told us the only way they managed to move therapies, including cannabis, forward and actually treat autism was pressure on the government from parents. I guess Israelis know how to push. Now UK parents fly to Tel Aviv to treat their child with autism, some others fly to California and I met one nice lady who takes her daughter to Italy.